Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
10.02% Fm, SH, 0.05% CsA----[1] 53
211C-CSar----[2] 93, 94
33 MPDN pulse + PDN + CSA----[1] 50
4ATGAM plus CsA with or without Eltrombopag[1] Eltrombopag---[1] 60
5Cohort 1: hATG, CsA, EPAG Day 14 to Month 6[1] Antilymphocyte immunoglobulin (horse)---[1] 60
6Cohort 2: hATG, CsA, EPAG Day 14 to Month 3[1] Antilymphocyte immunoglobulin (horse)---[1] 60
7Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6[1] Antilymphocyte immunoglobulin (horse)---[1] 60
8CsA----[8] 19, 49, 50, 53, 60, 63, 222, 228
9Cyclosporine A (CsA)[1] Cyclosporine[1] D00184 [5] PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬		[33] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬[2] 19, 60
10IST (ATG + CsA)----[1] 60
11L-CsA----[1] 228